Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
Merck
AstraZeneca
Baxter
Express Scripts

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

Agalsidase beta - Biologic Drug Details

See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for agalsidase beta

Identify potential brand extensions & biosimilar entrants

SponsorPhase
SanofiPhase 4
University Hospital, RouenN/A
Amicus TherapeuticsPhase 2

See all agalsidase beta clinical trials

Recent Litigation for agalsidase beta

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Shelbyzyme LLC v. Genzyme Corporation2009-10-14

See all agalsidase beta litigation

Pharmacology for agalsidase beta
Ingredient-typealpha-Glucosidases

Company Disclosures: US Patents for agalsidase beta

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genzyme FABRAZYME agalsidase beta VIAL; INTRAVENOUS 103979 001 2003-04-24   Start Trial Mount Sinai School of Medicine of the City of New York (New York, NY) 2039-02-26 RX Orphan company
Genzyme FABRAZYME agalsidase beta VIAL; INTRAVENOUS 103979 002 2003-04-24   Start Trial Mount Sinai School of Medicine of the City of New York (New York, NY) 2039-02-26 RX Orphan company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for agalsidase beta

These patents were identified by searching patent claims

Supplementary Protection Certificates for agalsidase beta

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0064 France   Start Trial PRODUCT NAME: AGALSIDASE BETA; REGISTRATION NO/DATE: EU/1/01/188/001-006 20010807
2013000092 Germany   Start Trial PRODUCT NAME: AGALSIDASE BETA; REGISTRATION NO/DATE: EU/1/01/188/001-006 20010803
2013 00060 Denmark   Start Trial PRODUCT NAME: AGALSIDASE BETA; REG. NO/DATE: EU/1/01/188/001-003 20010803
1942189/01 Switzerland   Start Trial FORMER OWNER: MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY, US
C/GB10/030 United Kingdom   Start Trial PRODUCT NAME: AGALSIDASE ALFA; REGISTERED: UK EU/1/01/189/001 20010807
2010 00020 Denmark   Start Trial
2010000028 Germany   Start Trial PRODUCT NAME: AGALSIDASE ALFA IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: EU/1/01/189/001 20010803
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Merck
McKesson
Boehringer Ingelheim
Medtronic
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.